The Business Council of the Vall d'Hebron Research Institute (VHIR), which includes CataloniaBIO members, met for the second time on 25 January. This board advises the VHIR directors and trustees, helping them identify opportunities, participate in joint projects and facilitate access to public and private resources.

The board has 15 members from finance, business and biotechnology, including companies and organisations such as Asebio, Fenin, Specific Pig, Grup Ferrer, ”la Caixa” Banking Foundation, AMETIC, Roche Diagnostics, Banco Sabadell, Laboratoris Esteve and Biocat. The board was created two years ago and is chaired by Lluís Bassat. 

The VHIR management team presented the institutional, scientific and financial results for 2017 to the board members, who considered them “excellent”. They also spoke about present and future projects, such as activating the Responsible Research and Innovation (RRI) policy and the importance of Vall d'Hebron research in the newly founded alliance of European hospitals. The main topic was the project for the New Research Building, a space that will be shared by everyone who conducts research at the institute. 

Photo: Board members at the meeting, including Ignasi Biosca, president of CataloniaBio at that time, and Jaume Amat, current president of CataloniaBio & HealthTech © VHIR